Pei-hua Lu

Hebei, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Clinical outcomes of offspring and matched unrelated donor transplants in relapsed or refractory severe aplastic anemia patients aged 40-50: a retrospective analysis from the CBMTR over the past decade.

Clinical outcomes of offspring and matched unrelated donor transplants in relapsed or refractory severe aplastic anemia patients aged 40-50: a retrospective analysis from the CBMTR over the past decade.

Journal: Bone marrow transplantation

Published: January 28, 2025

Comparable survival outcomes in HLA-Matched and haploidentical hematopoietic stem cell transplantation for severe aplastic anemia patients aged 40-50: A CBMTR Registry-based propensity score matching analysis over the last decade.

Comparable survival outcomes in HLA-Matched and haploidentical hematopoietic stem cell transplantation for severe aplastic anemia patients aged 40-50: A CBMTR Registry-based propensity score matching analysis over the last decade.

Journal: Cancer letters

Published: November 25, 2024

Correction: Hematopoietic stem cell transplantation activity in China 2022-2023. The proportions of peripheral blood for stem cell source continue to grow: a report from the Chinese Blood and Marrow Transplantation Registry Group.

Correction: Hematopoietic stem cell transplantation activity in China 2022-2023. The proportions of peripheral blood for stem cell source continue to grow: a report from the Chinese Blood and Marrow Transplantation Registry Group.

Journal: Bone marrow transplantation

Published: November 15, 2024

Hematopoietic stem cell transplantation activity in China 2022-2023. The proportions of peripheral blood for stem cell source continue to grow: a report from the Chinese Blood and Marrow Transplantation Registry Group.

Hematopoietic stem cell transplantation activity in China 2022-2023. The proportions of peripheral blood for stem cell source continue to grow: a report from the Chinese Blood and Marrow Transplantation Registry Group.

Journal: Bone marrow transplantation

Published: July 06, 2024

Ruxolitinib plus steroids for acute graft versus host disease: a multicenter, randomized, phase 3 trial.

Ruxolitinib plus steroids for acute graft versus host disease: a multicenter, randomized, phase 3 trial.

Journal: Signal transduction and targeted therapy

Published: May 22, 2024

Efficacy and safety of CD19 CAR-T cell therapy for acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation.

Efficacy and safety of CD19 CAR-T cell therapy for acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation.

Journal: International journal of hematology

Published: April 11, 2022

Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study.

Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study.

Journal: Blood cancer journal

Published: January 28, 2022

Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia.

Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia.

Journal: Cancer immunology, immunotherapy : CII

Published: January 27, 2021

Hematopoietic stem cell transplantation activity in China 2019: a report from the Chinese Blood and Marrow Transplantation Registry Group.

Hematopoietic stem cell transplantation activity in China 2019: a report from the Chinese Blood and Marrow Transplantation Registry Group.

Journal: Bone marrow transplantation

Published: August 19, 2020

Advances in the development of chimeric antigen receptor-T-cell therapy in B-cell acute lymphoblastic leukemia.

Advances in the development of chimeric antigen receptor-T-cell therapy in B-cell acute lymphoblastic leukemia.

Journal: Chinese medical journal

Published: January 25, 2020

Treatment with Humanized Selective CD19CAR-T Cells Shows Efficacy in Highly Treated B-ALL Patients Who Have Relapsed after Receiving Murine-Based CD19CAR-T Therapies.

Treatment with Humanized Selective CD19CAR-T Cells Shows Efficacy in Highly Treated B-ALL Patients Who Have Relapsed after Receiving Murine-Based CD19CAR-T Therapies.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 21, 2019

Showing 1-11 of 11

Last Updated: 09/26/2026